Active substance | Olorofim |
Holder | F2G Ltd |
Status | on hold |
Indication | invasive fungal infections in patients lacking alternative treatment options |
Public documents | Approbation |
Information for the patient | |
Informed consent | |
Last update | 27/06/2023 |